Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00934050 · ClinicalTrials.gov registry record · Phase 2

ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease

A Phase 2 study, sponsored by OPKO Health.

Completed
Registry status
Phase 2
Development phase
103
Enrollment target

NCT00934050: Completed Phase 2 study, sponsored by OPKO Health.

NCT00934050 is a Phase 2 study that has completed, run by OPKO Health. The registered enrollment target is 103 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00934050, a Phase 2 study, has completed, sponsored by OPKO Health.

COMPLETED
Registry status
Phase 2
Development phase
103 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.

Primary Outcome

Safety and Tolerability was assessed by the incidence of Treatment Emergent Adverse Events (TEAEs)

Interventions

  • DRUG ELND005 (scyllo-inositol)

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2009-06
Est. Completion 2011-06
Phase Phase 2
OPKO Health

32 total trials

What the finished NCT00934050 record still lists

NCT00934050 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower).

The record links to 0 conditions, and to 1 intervention - of which ELND005 (scyllo-inositol) is the first listed.

NCT00934050 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00934050 about?

NCT00934050 is a clinical study titled "ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease". The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.

What is the current status of trial NCT00934050?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2009-06. Estimated completion is 2011-06.

What interventions are being tested in trial NCT00934050?

The interventions under investigation include: ELND005 (scyllo-inositol) (DRUG).

Who is sponsoring clinical trial NCT00934050?

This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00934050's enrollment target sits among peer trials

103 664th of 2000 higher than 1,333 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00934050, the US trial registry maintained by the National Library of Medicine. NCT00934050 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.